Important milestone reached for evaxion biotech's evx-01 personalized cancer therapy

Copenhagen, denmark, sept. 21, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, reached an important milestone announcing today that it had enrolled its first patient in the global phase 2b clinical trial of evx-01, the company's personalized cancer therapy for the treatment of melanoma.
EVAX Ratings Summary
EVAX Quant Ranking